What Happened?

Shares of medical device company Integra LifeSciences (NASDAQ: IART) fell 3.5% in the afternoon session after the company issued a weak revenue forecast for the upcoming quarter and reported a significant drop in profitability, overshadowing its beats on fourth-quarter revenue and adjusted earnings. 

The medical device maker guided for first-quarter revenue of $382.5 million, which was 2.8% below what Wall Street analysts had anticipated. While fourth-quarter revenue of $434.9 million and adjusted earnings per share of $0.83 both topped expectations, other key metrics pointed to underlying issues. Revenue declined 1.7% year-over-year, and the company's operating margin fell sharply to 5.3% from 14.5% in the same period last year. Furthermore, free cash flow was negative $5.4 million, a significant reversal from a positive $21.14 million a year ago. This combination of a weak outlook and deteriorating profitability appears to have outweighed the headline beats, leading investors to sell off the stock.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Integra LifeSciences’s shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 3 days ago when the stock dropped 4.2% on the news that the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.

Integra LifeSciences is down 6.9% since the beginning of the year, and at $11.19 per share, it is trading 53.3% below its 52-week high of $23.95 from March 2025. Investors who bought $1,000 worth of Integra LifeSciences’s shares 5 years ago would now be looking at an investment worth $163.67.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.